Women who are pregnant dont have to stop all of their treatments during pregnancy. Some can be safely treated for their psoriasis or eczema, according to a presentation today at the annual meeting of the American Academy of Dermatology.
Women who are pregnant and who have psoriasis or eczema often have limited options. The evidence about the effect that the systemic medications might have on pregnant women and their fetuses is limited.
But women deserve more than just topical treatment and moisturizers, and doctors may be more restrictive than necessary, Elizabeth Kiracofe, M.D., a dermatologist in private practice in Chicago, said during a presentation today at the annual meeting of the American Academy of Dermatology in New Orleans.
We are more restrictive with both systemics and topical medications in our patients who have atopic dermatitis and psoriasis in a way that is not scientifically backed, she said. We may be doing a disservice to patients by being too restrictive in our prescribing patterns. We may have concerns, and there are uncertainties, but these patients deserve to be treated because there's also risk of nontreatment. These patients have a chronic immune-mediated inflammatory disease and theyre pregnant. Having an uncontrolled chronic immune mediated inflammatory disease is also not healthy in pregnancy.
Inadequate control of disease can lead to flares and infections and even septicemia, Kiracofe said. Additionally, she said, depression is more common in women with psoriasis than in healthy women without psoriasis. And 21% of pregnant women who have psoriasis suffer from depression, compared with 10% of non-psoriasis patients.
In the United States, 4.6% of women have atopic dermatitis, and 3.2% of women have psoriasis. About 75% of women are diagnosed before the age of 40. At the same time, the representation of women in psoriasis studies has decreased. In a recent JAMA study, investigators found that clinical studies with least 45% of women in the enrolled population decreased from 87.2% in the 2010 to 2015 timeframe to 29.5% in the 2015 to 2020 timeframe.
Kiracofe acknowledged the treatment choices for pregnant patients with atopic dermatitis are complicated. There are no large clinical studies on the possible effects and side-effect of biologics on conception, pregnancy and lactation.
When treating pregnant women, its important to use the science, Kiracofe said. We cant just base decisions on just the label; we need to know the pathophysiology, we need to know how the body works. And we need to have a shared decision-making process and talk with our patients because that is a really important conversation.
An important piece of the puzzle in the use of biologics in psoriasis and atopic dermatitis during pregnancy is the degree of immune suppression the infant experiences within the few first few months of life.
Its important to think about the impact of using biologics in the second and third trimester. Thats a really big frameshift when thinking about medication interacting with our patients. Were taught from medical school to think about the first trimester fetal malformations. But for these type of systemic medications, we actually want to be thinking in the second and third trimester.
Kiracofe described how the placental Fc receptor "grabs." The Fc receptor is instrumental in allowing medications to cross the placenta. Cimzia (certolizumab) is the only biologic with a confirmed safety profile during pregnancy and lactation with no increased mortality rate for the fetus, Kiracofe told an audience at the dermatology organization's annual meeting. Cimzia is a TNF-alpha inhibitor that doesnt bind to the placental Fc receptor.
Cimzia was approved in September 2013 by the FDA as a treatment of active psoriatic arthritis and in May 2018 as a treatment of moderate-to-severe psoriasis in adults. It is also approved for treating rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
More here:
Treatment of Atopic Dermatitis and Psoriasis in People Who Are ... - Managed Healthcare Executive
- Dermatology Partners Opens State-of-the-Art Dermatopathology Laboratory - citybiz - February 25th, 2025 [February 25th, 2025]
- Ethical Considerations and Guidance of Cosmeceuticals in Pediatric Care - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- AI in Dermatology: Emerging Insights and Diverging Perspectives - MD Magazine - February 25th, 2025 [February 25th, 2025]
- Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical... - February 25th, 2025 [February 25th, 2025]
- Aesthetic Treatments: More Than Just Enhancements, A Path to Empowerment - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- Samitivej to advance dermatology and aesthetic medicine in new partnership - Healthcare Asia - February 25th, 2025 [February 25th, 2025]
- Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with... - February 25th, 2025 [February 25th, 2025]
- U.S. Dermatology Partners Ranked the No. 1 Dermatology Group in the Nation by Castle Connolly - PR Newswire - February 3rd, 2025 [February 3rd, 2025]
- Alopecia Areata Risk May be Associated With Serum Vitamin D and Zinc Levels - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Age at Melanoma Diagnosis Varies by Sex, Anatomic Site, and Tumor Thickness - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Dermatology Medications and Solutions Market Poised to Growth USD 51.7 Billion by 2032 with Thriving CAGR of - EIN News - January 23rd, 2025 [January 23rd, 2025]
- Optimizing Care for Patients with Urticaria - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Advancing Care With Laser and Light-Based Technology in Dermatology - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Online Dermatology Consultation Market: CAGR of 15.4% Expected by 2025 Due to Increasing Skin Health Awareness - openPR - January 23rd, 2025 [January 23rd, 2025]
- VP-315 Demonstrates Positive Topline Results in Basal Cell Carcinoma - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- AI and the Future of Cosmetic Dermatology: Experts Weigh in - Medscape - January 23rd, 2025 [January 23rd, 2025]
- When and How to Employ the Buy and Bill Model - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Innovating Scalp Care: How Research and Education Drive Solutions - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Rare Overlap of 2 Autoinflammatory Keratinization Diseases Observed in Single Lesion - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Expanding Laser Benefits for Diverse Patient Populations - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Kwon Min-ah, a former member of the group AOA, became the head of the dermatology consultation offic.. - - January 15th, 2025 [January 15th, 2025]
- Top 5 Dermatology Articles of 2024 - Managed Healthcare Executive - January 1st, 2025 [January 1st, 2025]
- DEI programs, sun safety: Read this years top practice management articles in dermatology - Healio - January 1st, 2025 [January 1st, 2025]
- Cutaneous Connection 2024: Top Dermatology Podcast Episodes and Insights of the Year - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Top Insights and Highlights from Dermatology Times' Interview Intersection: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Reviewing Major Dermatologic Studies of the Year: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Peak Dermatology in Visalia hopes to provide more skin services and treatment to the area - KFSN-TV - December 23rd, 2024 [December 23rd, 2024]
- Krystal Tawney of Pinnacle Dermatology celebrates 10 years of business in the Greenbrier Valley - Real WV - December 23rd, 2024 [December 23rd, 2024]
- Supporting Pediatric Patients With AD and Their Caregivers - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Photodynamic Therapy is an Effective, Long-Term Treatment for Actinic Keratosis - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Advanced Dermatology to pay $15G fine after doctor refused to perform procedure on HIV-infected patient - Newsday - December 9th, 2024 [December 9th, 2024]
- Efficacy of Combining Postbiotic Formulation with Microneedling for Acne - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Opioid-Prescribing Trends in Dermatology From 2014 to 2020 in the United States - Cureus - November 28th, 2024 [November 28th, 2024]
- Amid challenges, the Baton Rouge dermatology industry is evolving - Greater Baton Rouge Business Report - November 28th, 2024 [November 28th, 2024]
- Polynucleotide Therapy Shows Promise in Scar and Burn Management - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Revolutionizing Dermatology: How Emerging Technologies are Shaping the Future of Skin Care - Spherical Insights - November 28th, 2024 [November 28th, 2024]
- Dermatology OTC Medications Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033 - openPR - November 28th, 2024 [November 28th, 2024]
- Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases: Part 2 - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Patient Education and Novel Topical Therapies for AD - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- TikTok dermfluencers have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week -... - November 20th, 2024 [November 20th, 2024]
- $500,000 Pay, Predictable Hours: How Dermatology Became the It Job in Medicine - The Wall Street Journal - November 20th, 2024 [November 20th, 2024]
- Empowering Dermatology PAs Through Education and Career Support - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- U.S. Dermatology Partners Announces the Opening of Stephenville, Texas Office - PR Web - November 20th, 2024 [November 20th, 2024]
- $500,000 Pay, Predictable Hours: How Dermatology Became the It Job in Medicine - Yahoo! Voices - November 20th, 2024 [November 20th, 2024]
- FRONTIER-2 Study Evaluates Safety and Efficacy of Tozorakimab in Patients with AD - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- Improving Care and Innovations in Vitiligo and Atopic Dermatitis: Part 1 - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- In the United States, the dermatology concentration of doctors is also noticeable.The Wall Street Jo.. - - November 20th, 2024 [November 20th, 2024]
- Dermatology Diagnostic Devices and Therapeutics Market Size, Trends and Industry Growth Forecast to 2032 - openPR - November 20th, 2024 [November 20th, 2024]
- POLL: What Topics Are You Looking Forward to at SDPA Fall 2024? - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- Digital tool aims to tackle long dermatology waits - Health and Care News Scotland - November 20th, 2024 [November 20th, 2024]
- Is AI Coming for My Job?: Familiarizing Clinicians with AI Tools and Their Role in Dermatology - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Almiralls Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology... - November 12th, 2024 [November 12th, 2024]
- Updates on the Latest Cosmetic Treatments in Medical Care - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Jenny Murase, MD: Emerging Therapies Bring Hope to Patients with Persistent Itch - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- POLL: Are You Attending the Elevate-Derm West Conference? - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Memorial Health System is re-opening of Department of Dermatology - Parkersburg News - October 26th, 2024 [October 26th, 2024]
- Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology... - October 26th, 2024 [October 26th, 2024]
- What To Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD - MD Magazine - October 26th, 2024 [October 26th, 2024]
- Navigating Complexities and Unmet Needs of Chronic Hand Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Schweiger Dermatology Group Expands in Florida with the Acquisition of ClearlyDerm, Adding 5 New Offices in South Florida - PR Newswire - October 26th, 2024 [October 26th, 2024]
- Leo Pharma tells doctors to 'Talk to the Hand' in new dermatology campaign - FiercePharma - October 26th, 2024 [October 26th, 2024]
- Dermatology Partners To Expand Maryland Presence With New Westminster Clinic, Hosts Free Skin Cancer Screenings For Veterans On November 11 - citybiz - October 26th, 2024 [October 26th, 2024]
- Peter Lio, MD: The Latest Perspectives on Pathophysiology and Treatment of Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell... - October 26th, 2024 [October 26th, 2024]
- Dermatology Patients Taking Biologics are Wary About Most Vaccines - Medpage Today - October 13th, 2024 [October 13th, 2024]
- Safe and Effective: Upadacitinib Shows Promise in PN Treatment - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- SPONSORED: First Care, Heartland Dermatology team up again for free health screening event - Hays Post - October 13th, 2024 [October 13th, 2024]
- Global Dermatology Drugs Market to Worth Over US$ 50.42 Billion By 2032 | Astute Analytica - GlobeNewswire - October 13th, 2024 [October 13th, 2024]
- Working to Improve Mental Health - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- Bimekizumab Demonstrates Safety and Efficacy in Elderly Patients with Psoriasis - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- UCB at EADV 2024: committed to advancing care in immuno-dermatology - UCB - October 2nd, 2024 [October 2nd, 2024]
- Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- Expert Insights Into Handling Treatment Challenges and Site-Specific Concerns in Vitiligo Management - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]